On June 23, 2020, the GNS team was joined by Craig Davis, Sr. Director of Translational Oncology at Pfizer, to discuss the use of our AI platform for identifying drivers of immune checkpoint inhibitor response. We covered how companies leading the charge on ICI development are faced with many questions including:

1. What are the molecular drivers of tumor response?
2. What biomarkers, in addition to the currently approved ones, better identify the subset of patients who see clinical benefit from ICI therapy for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC)?
3. How can we turn non-responsive tumors (cold) into responsive tumors (hot)?

Access the recording by filling out the form to the right.